StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for XBIT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $2.54 | $2.50 | -1.38% | 0.0M |
| 05-15 | $2.47 | $2.46 | -0.40% | 0.0M |
| 05-18 | $2.46 | $2.40 | -2.44% | 0.0M |
| 05-19 | $2.43 | $2.37 | -2.47% | 0.0M |
| 05-20 | $2.36 | $2.39 | +1.27% | 0.0M |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-37.51M | $-28.92M | $-20.40M | $-7.14M |
Net Income | $-24.56M | $-19.92M | $-12.56M | $-3.82M |
EPS (Diluted) | $-0.81 | $-0.65 | $-0.41 | $-0.13 |
Total Assets | $226.62M | $229.60M | $235.14M | $242.12M |
Total Liabilities | $7.77M | $6.94M | $6.07M | $5.22M |
Cash & Equivalents | $200.02M | $202.19M | $143.39M | $152.48M |
Free Cash Flow OCF − CapEx | $-19.09M | $-15.54M | $-14.02M | $-4.81M |
Shares Outstanding | 30.44M | 30.44M | 30.44M | 30.44M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.